Medtronic Reports Third Quarter Financial Results

Go back to Medtronic Reports Third Quarter Financial Results

Medtronic's (MDT) Weak Margins Spur PT Reduction - Leerink Partners

March 2, 2016 6:41 AM EST

Leerink Partners analyst, Danielle Antalffy, cut her PT on Medtronic (NYSE: MDT) as sales growth was offset by weaker margins. PT goes to $82 from $84 and Market Perform rating remains unchanged.

MDT shares traded lower yesterday driven by less positive operating leverage than expected, as... More

Buy Medtronic (MDT) Weakness, Says Deutsche Bank

March 1, 2016 3:02 PM EST

Deutsche Bank earlier reiterated a Buy rating on Medtronic, Inc. (NYSE: MDT) with a price target of $90. Analyst Kristen Stewart said investors should buy weakness.

The analyst explained, "We continue to rate MDT a Buy. Why? We see a number of recently and... More

Needham & Company Cuts Price Target on Medtronic (MDT) as 3Q Revenue Misses Mark

March 1, 2016 11:50 AM EST

Needham & Company maintained a Buy rating on Medtronic, Inc. (NYSE: MDT), and cut the price target to $88.00 (from $91.00), following the company's 3Q earnings report. Revenue was reported at $6.934B vs. the consensus of $6.987B. Adjusted EPS was reported at $1.06, in-line with consensus estimates. MDT... More

Medtronic (MDT) Reports In-Line Q3 EPS

March 1, 2016 6:47 AM EST

Medtronic (NYSE: MDT) reported Q3 EPS of $1.06, in-line with the analyst estimate of $1.06. Revenue for the quarter came in at $6.93 billion versus the consensus estimate of $6.99 billion.

GUIDANCE:

Medtronic still sees FY16 EPS of $4.36 - $4.40, versus the consensus of $4.38.

For earnings history and earnings-related data on Medtronic (MDT) click here.

... More